For the better part of two years, compounding pharmacies operated in a regulatory gray zone that allowed them to produce versions of semaglutide and tirzepatide at a fraction of branded prices. That era is over. With the FDA's determination that the shortage has ended and its subsequent enforcement actions, millions of patients who relied on compounded GLP-1 medications now face a stark question: what comes next?
How We Got Here
The compounding exception was never intended to be a permanent market feature. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of FDA-approved drugs only when those drugs are listed on the FDA's shortage database. When semaglutide and tirzepatide demand vastly outstripped supply in 2023–2024, compounders stepped into the gap.
The scale of this market surprised everyone. By some estimates, compounded GLP-1 prescriptions accounted for 30–40% of all GLP-1 prescriptions at their peak. Patients paid $200–400 per month instead of $1,000+. An entire ecosystem of telehealth platforms, cash-pay clinics, and direct-to-consumer services was built on the compounding model.
The Options on the Table
Option 1: Transition to branded medications. For patients with commercial insurance that covers GLP-1 drugs, this is the most straightforward path. Manufacturer savings programs can reduce out-of-pocket costs significantly. Novo Nordisk's recent price cuts brought Wegovy to approximately $675 per month, and their direct-to-patient programs offer further reductions.
Option 2: Explore the new oral options. The FDA's April 2026 approval of orforglipron (Foundayo) introduces the first oral GLP-1 for weight management. While the 7–8% average weight loss is more modest than injectable options, the convenience and potentially lower price point make it a viable alternative for many patients.
Option 3: Seek comprehensive care programs. Some medical practices have developed integrated GLP-1 protocols that bundle medication management with metabolic monitoring, nutritional support, and body composition tracking. These programs often negotiate medication pricing and provide the clinical infrastructure that standalone prescriptions lack.
Option 4: Advocate for policy change. Patient advocacy groups are pushing for expanded Medicare and Medicaid coverage of obesity medications. The Medicare coverage provision taking effect in January 2027 at $274/month represents a significant step, but millions remain without affordable access.
The Deeper Problem
The compounding era exposed a fundamental truth about the GLP-1 market: when effective medications are priced beyond reach, patients will find alternatives. The fact that millions turned to compounded versions was not a failure of regulation—it was a failure of pricing.
Now that the loophole is closed, the pharmaceutical industry faces renewed pressure to make these medications accessible. The recent price reductions suggest manufacturers understand this reality. But for the patients caught in the transition, the immediate challenge is navigating a suddenly changed landscape.
What We Recommend
Patients currently on compounded GLP-1 medications should take three immediate steps. First, schedule a consultation with a physician—not a telehealth prescription service, but a comprehensive metabolic care provider. Second, get baseline labs and body composition data to understand your current metabolic status. Third, explore all coverage options including manufacturer programs, insurance appeals, and comprehensive care models that may offer better pricing through volume relationships.
The compounding loophole may be closed, but the need it addressed—affordable access to effective obesity treatment—remains wide open.